Moviprep

Polyethylene glycol, the active ingredient in Moviprep, is a laxative presented as a powder for oral solution for oral use. It is employed to cleanse the bowel before diagnostic procedures such as colonoscopy and sigmoidoscopy, facilitating clear visualization of the intestinal mucosa.

GNH USA supplies Moviprep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant packaging for global distribution. Our logistics network ensures timely delivery to healthcare facilities across Europe, Asia, Africa and the Americas.

Moviprep is an osmotic laxative used for bowel cleansing prior to endoscopic examinations of the lower gastrointestinal tract.

Colonoscopic preparation: provides thorough cleansing of the entire colon to improve visualization during the procedure. Sigmoidoscopic preparation: clears the distal colon and rectum, enabling accurate assessment of the sigmoid and rectal mucosa. Radiographic contrast studies: prepares the colon for barium enema by removing residual stool.

Moviprep may be associated with several adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Abdominal cramping: intermittent discomfort in the abdomen. - Bloating: sensation of abdominal fullness. - Diarrhea: loose, watery stools. - Vomiting: occasional expulsion of stomach contents. - Flatulence: increased gas production.

Serious or Rare Side Effects: - Severe dehydration: marked loss of body fluids requiring medical attention. - Electrolyte imbalance: abnormal sodium or potassium levels, such as hyponatremia. - Renal impairment: reduced kidney function in susceptible individuals. - Allergic reaction: rare cases of anaphylaxis or severe skin rash.

Before prescribing Moviprep, clinicians should evaluate patient-specific factors to minimise risks.

Assess renal function: evaluate kidney health before administration. Check electrolyte status: correct abnormalities prior to use. Avoid in severe constipation: consider alternative therapy. Monitor for dehydration: ensure adequate fluid intake. Pregnancy and lactation: use only if benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture and heat.

Moviprep can interact with other medications that affect fluid and electrolyte balance.

Major Interactions (Avoid): - Concomitant use with high‑dose oral sodium phosphate: risk of severe electrolyte disturbances. - Loop diuretics: may exacerbate dehydration and electrolyte loss. - Anticholinergic agents: can reduce bowel motility, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Opioid analgesics: may counteract laxative effect, requiring dose adjustment. - Antacids containing magnesium or aluminum: may alter osmotic balance. - Probiotic supplements: generally safe but monitor for gastrointestinal symptoms.